Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK13 | O15264 | 12/20 | 0.58 |
| ▸ | MAPK12 | P53778 | 12/20 | 0.58 |
| ▸ | MAPK11 | Q15759 | 12/20 | 0.58 |
| ▸ | MAPK14 | Q16539 | 12/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | JAK2 | O60674 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | GFER | P55789 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | CDK8 | P49336 | 1/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1012616 | 0.90 | MAPK13 (0.66) | MAPK13MAPK12MAPK11MAPK14GAA | |
| SCHEMBL378957 | 0.89 | MAPK14 (0.68) | MAPK13MAPK12MAPK11MAPK14GAA | |
| SCHEMBL1013690 | 0.88 | MAPK13 (0.59) | MAPK13MAPK12MAPK11MAPK14GAA | |
| SCHEMBL1012997 | 0.87 | MAPK14 (0.66) | MAPK13MAPK12MAPK11MAPK14GAA | |
| SCHEMBL1013743 | 0.87 | MAPK14 (0.73) | MAPK13MAPK12MAPK11MAPK14GAA | |
| SCHEMBL1793950 | 0.87 | MAPK14 (0.58) | MAPK13MAPK12MAPK11MAPK14GAA | |
| Carbamic Acid SCHEMBL1780358 | 0.87 | MAPK13 (0.62) | MAPK13MAPK12MAPK11MAPK14GAA | |
| SCHEMBL1013422 | 0.86 | MAPK13 (0.69) | MAPK13MAPK12MAPK11MAPK14GAA | |
| SCHEMBL19749990 | 0.86 | ALDH1A1 (0.56) | MAPK13MAPK12MAPK11MAPK14GAA | |
| SCHEMBL16054415 | 0.85 | CDK8 (0.64) | MAPK13MAPK12MAPK11MAPK14GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180086741-A1 | KINASE INHIBITORS | OXULAR ACQUISITIONS LIMITED (GB) | 2018-03-29 | — | — | US | disclosed |
| US-9850233-B2 | Kinase inhibitors | RESPIVERT LIMITED (GB) | 2017-12-26 | — | — | US | disclosed |
| US-20160318909-A1 | KINASE INHIBITORS | OXULAR ACQUISITIONS LIMITED (GB) | 2016-11-03 | — | — | US | disclosed |
| US-20160016934-A1 | KINASE INHIBITORS | TOPIVERT PHARMA LIMITED (GB) | 2016-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180086741-A1 | KINASE INHIBITORS | SYK, BTK, SRC | MAPK13 77/4885MAPK12 124/4885MAPK11 231/4885 |
| US-20160016934-A1 | KINASE INHIBITORS | SYK, LYN, BTK | MAPK13 68/4885MAPK12 176/4885MAPK11 182/4885 |
| US-20160318909-A1 | KINASE INHIBITORS | SYK, LYN, BTK | MAPK13 67/4885MAPK12 179/4885MAPK11 186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.